Posted by Michael Wonder on 01 Apr 2023
Schedule of Pharmaceutical Benefits - 1 April 2023
1 April 2023 - The April 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The April issue of the Schedule includes a few major new/revised listings:
- Mepolizumab (Nucala) - new indication
- Nivolumab (Opdivo) - new indication
- Ruxolitinib phosphate (Jakavi) - new indications
- Sapropterin dihydrochloride (Kuvan) - restriction change
